High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: A preliminary report

Funding

Without any relevance to this work, R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. Without relevance to this work, W. Wadsak received within the last three years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (Fürstenfeldbruck, Germany). He is a part-time employee of CBmed GmbH (Graz, Austria) and a co-founder of MINUTE medical GmbH (Vienna, Austria). G.S. Kranz received travel grants from Roche, AOP Orphan Pharmaceuticals and Pfizer. M. Spies received travel grants from Janssen and AOP Orphan Pharmaceuticals, speaker honoraria from Janssen and Austroplant, and workshop participation from Eli Lilly. All other authors report no potential conflict of interest regarding this publication. This study was supported by a grant from the Austrian Science Fund to R. Lanzenberger (FWF grant number K LI 50 4 ). M. Murgas is funded by the Austrian Science Fund (FWF), D OC 33-B2 7 . L. Rischka was a recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna. This study was supported by a grant from the Austrian Science Fund to R. Lanzenberger (FWF grant number KLI 504). M. Murgas is funded by the Austrian Science Fund (FWF), DOC 33-B27. L. Rischka was a recipient of a DOC Fellowship of the Austrian Academy of Sciences at the Department of Psychiatry and Psychotherapy, Medical University of Vienna. The authors are grateful to S. Kasper, K. Papageorgiou, A. Komorowski, T. Vanicek, A. Kautzky, G. Gryglewski, M. Hienert, J. Jungwirth, J. Unterholzner, M. Godbersen, P. Michenthaler, A. Basaran for medical support, and G. James, S. Ganger, M. Kl?bl, B. Spurny, R. Seiger, H. Sigurdardottir, B. Zhang for technical support, and E. Sittenberger, V. Ritter and the diploma students of the Neuroimaging Labs for subject recruitment and administrative support. We thank N. Berroteran-Infante and N. Schindler for support in radiosyntheses and the PET team for the measurements. The authors are especially grateful to all study subjects for participating. The scientific project was performed with the support of the Medical Imaging Cluster of the Medical University of Vienna., Without any relevance to this work, R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. Without relevance to this work, W. Wadsak received within the last three years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (F?rstenfeldbruck, Germany). He is a part-time employee of CBmed GmbH (Graz, Austria) and a co-founder of MINUTE medical GmbH (Vienna, Austria). G.S. Kranz received travel grants from Roche, AOP Orphan Pharmaceuticals and Pfizer. M. Spies received travel grants from Janssen and AOP Orphan Pharmaceuticals, speaker honoraria from Janssen and Austroplant, and workshop participation from Eli Lilly. All other authors report no potential conflict of interest regarding this publication.